Morgan Stanley’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-884
| Closed | -$2.39K | – | 7844 |
|
|
2023
Q1 | $2.39K | Hold |
884
| – | – | ﹤0.01% | 7206 |
|
|
2022
Q4 | $3.53K | Hold |
884
| – | – | ﹤0.01% | 7240 |
|
|
2022
Q3 | $7K | Buy |
884
+49
| +6% | +$596 | ﹤0.01% | 7197 |
|
|
2022
Q2 | $10K | Sell |
835
-395
| -32% | -$3.71K | ﹤0.01% | 7222 |
|
|
2022
Q1 | $21K | Buy |
1,230
+994
| +421% | +$31.9K | ﹤0.01% | 7137 |
|
|
2021
Q4 | $15K | Sell |
236
-116
| -33% | -$6.75K | ﹤0.01% | 7334 |
|
|
2021
Q3 | $24K | Sell |
352
-2,287
| -87% | -$164K | ﹤0.01% | 7045 |
|
|
2021
Q2 | $184K | Buy |
2,639
+2,523
| +2,175% | +$137K | ﹤0.01% | 6060 |
|
|
2021
Q1 | $8K | Sell |
116
-115
| -50% | -$8.72K | ﹤0.01% | 7018 |
|
|
2020
Q4 | $14K | Sell |
231
-55
| -19% | -$3.2K | ﹤0.01% | 6554 |
|
|
2020
Q3 | $17K | Buy |
286
+76
| +36% | +$6.79K | ﹤0.01% | 6123 |
|
|
2020
Q2 | $27K | Buy |
210
+195
| +1,300% | +$17.2K | ﹤0.01% | 5924 |
|
|
2020
Q1 | $1K | Sell |
15
-3
| -17% | -$294 | ﹤0.01% | 6515 |
|
|
2019
Q4 | $2K | Buy |
+18
| New | +$2.44K | ﹤0.01% | 6524 |
|
|
2019
Q2 | – | Sell |
-319
| Closed | -$144K | – | 6816 |
|
|
2019
Q1 | $144K | Sell |
319
-30
| -9% | -$13.1K | ﹤0.01% | 5223 |
|
|
2018
Q4 | $160K | Sell |
349
-167
| -32% | -$104K | ﹤0.01% | 5371 |
|
|
2018
Q3 | $470K | Buy |
516
+152
| +42% | +$100K | ﹤0.01% | 5038 |
|
|
2018
Q2 | $213K | Sell |
364
-75
| -17% | -$48.9K | ﹤0.01% | 5509 |
|
|
2018
Q1 | $286K | Buy |
439
+373
| +565% | +$280K | ﹤0.01% | 5310 |
|
|
2017
Q4 | $24K | Buy |
66
+8
| +14% | +$3.05K | ﹤0.01% | 6030 |
|
|
2017
Q3 | $18K | Buy |
58
+40
| +222% | +$15.2K | ﹤0.01% | 6051 |
|
|
2017
Q2 | $9K | Buy |
+18
| New | +$13.6K | ﹤0.01% | 6268 |
|
|
2016
Q2 | – | Hold |
0
| – | – | – | 6716 |
|
|
2016
Q1 | – | Hold |
0
| – | – | – | 6784 |
|
|
2015
Q4 | – | Hold |
0
| – | – | – | 6854 |
|
|
2015
Q3 | – | Sell |
-10
| Closed | -$21K | – | 6773 |
|
|
2015
Q2 | $21K | Buy |
+10
| New | +$25.5K | ﹤0.01% | 6128 |
|
Morgan Stanley's HTGM Position: Q2 2023 in Review
Morgan Stanley sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q2 2023, closing a stake of 884 shares — an estimated $2.39K sold.
Morgan Stanley first reported a position in HTGM in Q2 2015 and held it in 23 quarters. The position peaked at $470K in Q3 2018. 0 funds tracked by Wall St. Rank hold HTGM as of Q2 2023.
- Morgan Stanley reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Morgan Stanley sold 884 HTG Molecular Diagnostics, Inc. Common Stock shares in Q2 2023, an estimated $2.39K.
- Morgan Stanley first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q2 2015 and held it in 23 quarters.
- Morgan Stanley's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $470K in Q3 2018.
- 0 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q2 2023.
Based on Morgan Stanley's 13F filing for Q2 2023, filed 14 Aug 2023.